My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

24.36 -0.21 (-0.85%)

Streaming Delayed Price Updated: 9:36 AM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >

This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally ↗

February 01, 2026

Centessa Pharmaceuticals develops therapies for rare and serious diseases, advancing a pipeline of clinical-stage and emerging candidates.

Via The Motley Fool

Topics ETFs

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

January 14, 2026

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

December 11, 2025

Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors

From Centessa Pharmaceuticals plc

Via GlobeNewswire

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Why Centessa Pharmaceuticals Stock Crushed the Market Today ↗

November 12, 2025

Investors were optimistic about the company potentially reaping $250 million in gross proceeds from an equity offering.

Via The Motley Fool

Neural Gold Rush: Is Brain Data the Most Precious Commodity of the Century?

November 12, 2025

As the digital age continues its relentless march, a new contender has emerged for the title of the world's most valuable commodity: neural data. Far surpassing traditional resources like oil or even...

Via MarketMinute

Topics Artificial Intelligence Economy

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

November 07, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

November 05, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Domino's Pizza Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 20, 2025

Via Benzinga

CENTESSA PHARMACEUTICALS-ADR (NASDAQ:CNTA) Shows Strong Technical Setup for Potential Breakout ↗

October 17, 2025

CNTA stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout for traders.

Via Chartmill

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗

September 12, 2025

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Via Benzinga

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

September 03, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

August 12, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗

July 21, 2025

All four companies are testing out orexin agonists to improve the symptoms of narcolpesy.

Via Investor's Business Daily

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

June 16, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 19, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

May 14, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday ↗

May 08, 2025

Via Benzinga

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

March 24, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.